Investigations on genesis of the hyperploidy require genetically modified cells to standardize the genetic backgrounds.
This is done by introducing new genes into embryonic stem cells in tissue culture, selecting the particular genetic variant that is desired, and then inserting the genetically modified cells into mouse embryos.
Then they implanted anywhere from 100 million to 400 million of these genetically modified cells into the patients' abdomens, under general anesthesia.
Biopharming, as it is sometimes called, may one day be an inexpensive way to produce large volumes of certain proteins, like insulin for diabetes or antibodies to treat cancer, that are now made in vats of genetically modified cells.
A third category of research, using stem cells or genetically modified cells (e.g., glial cells) that are transplanted into the zone of injury, seeks to replace damaged cells with substitute neurons or other cells that can restore function.
The occurrence of such genetically modified cells may lead to lens opacification.
However, these genetically modified cells easily lose critical phenotypes and stable genotypes because of insertional mutagenesis.
Selection of genetically modified cells is a critical step to engineer the cells with desired properties.
Transfected or other genetically modified cells can be selected by the traditional microbiological cloning.
Populations containing multiple species are important in natural ecosystems, well-defined processes, wastewater treatment, and systems using genetically modified cells.
Therefore, (transient or stable) genetically modified cells may be reasonably thought to resist oxidative stress induced damage.
